Oxford University spinout Dark Blue Therapeutics acquired to advance leukaemia treatment

Published on March 19, 2026

Oxford University spinout Dark Blue Therapeutics has been acquired by global biotechnology company Amgen in a deal worth up to US$840 million, marking a major milestone for Oxford-led cancer research and innovation. The deal reflects years of collaborative, multidisciplinary work across the University and its partners to translate fundamental research into promising new medicines.
Continue reading on website
Other news

GSK, University of Oxford and Imperial College London launch centre to create computer models of lungs, liver, kidneys and cartilage

March 19, 2026
A new research centre backed with £11 million from GSK will build open-source digital twins of organs for in-silico research to advance disease understanding and speed up development of new drugs.

Blood test may improve survival of childhood cancer in Africa

March 19, 2026
A simple blood test could speed up diagnosis and improve outcomes for children with Africa’s most common childhood cancer.